公开(公告)号：US20090202497A1

公开(公告)日：2009-08-13

申请号：US12064525

申请日：2006-08-22

申请人： Joel F. Habener ,  James F. List ,  Svetlana Mojsov

发明人： Joel F. Habener ,  James F. List ,  Svetlana Mojsov

IPC分类号： A61K35/12 ,  A61K38/16 ,  G01N33/53

CPC分类号： A61K38/26

摘要： The present invention relates to the use of GLP-I, GLP-I derivatives or GLP-I fragments for skin regeneration or hair growth in mammals. As used for skin regeneration, GLP-I, GLP-I derivatives or GLP-I fragments can be applied to dermal wounds including burns, lacerations, cuts and scrapes. As used for hair growth, GLP-I, GLP-I derivatives or GLP-I fragments can be applied to humans suffering from alopecia, or baldness. GLP-I, GLP-I derivatives or GLP-I fragments can also be used to stimulate hair growth in animals raised for their pelts. GLP-I, GLP-I derivatives or GLP-I fragments can also be used in the redifferentiation of endothelial or skin cells into insulin producing cells, as a treatment for patients suffering from diabetes.

摘要翻译： 本发明涉及GLP-1，GLP-1衍生物或GLP-1片段用于哺乳动物皮肤再生或毛发生长的用途。 用于皮肤再生时，GLP-1，GLP-1衍生物或GLP-1片段可用于皮肤伤口，包括烧伤，撕裂，切口和刮痕。 用于毛发生长的GLP-1，GLP-1衍生物或GLP-1片段可用于患有脱发或秃发的人。 GLP-1，GLP-1衍生物或GLP-1片段也可用于刺激为其毛皮提升的动物中的毛发生长。 GLP-1，GLP-1衍生物或GLP-1片段也可用于将内皮细胞或皮肤细胞再分化为产生胰岛素的细胞，作为患有糖尿病的患者的治疗。

公开(公告)号：US20120101038A1

公开(公告)日：2012-04-26

申请号：US13224371

申请日：2011-09-02

申请人： Joel F. Habener ,  James F. List ,  Svetlana Mojsov

发明人： Joel F. Habener ,  James F. List ,  Svetlana Mojsov

IPC分类号： A61K38/26 ,  A61M37/00 ,  A61M5/00 ,  A61P17/14

CPC分类号： A61K38/26

摘要： The present invention relates to the use of GLP-I, GLP-I derivatives or GLP-I fragments for skin regeneration or hair growth in mammals. As used for skin regeneration, GLP-I, GLP-I derivatives or GLP-I fragments can be applied to dermal wounds including burns, lacerations, cuts and scrapes. As used for hair growth, GLP-I, GLP-I derivatives or GLP-I fragments can be applied to humans suffering from alopecia, or baldness. GLP-I, GLP-I derivatives or GLP-I fragments can also be used to stimulate hair growth in animals raised for their pelts. GLP-I, GLP-I derivatives or GLP-I fragments can also be used in the redifferentiation of endothelial or skin cells into insulin producing cells, as a treatment for patients suffering from diabetes.

摘要翻译： 本发明涉及GLP-1，GLP-1衍生物或GLP-1片段用于哺乳动物皮肤再生或毛发生长的用途。 用于皮肤再生时，GLP-1，GLP-1衍生物或GLP-1片段可用于皮肤伤口，包括烧伤，撕裂，切口和刮痕。 用于毛发生长的GLP-1，GLP-1衍生物或GLP-1片段可用于患有脱发或秃发的人。 GLP-1，GLP-1衍生物或GLP-1片段也可用于刺激为其毛皮提升的动物中的毛发生长。 GLP-1，GLP-1衍生物或GLP-1片段也可用于将内皮细胞或皮肤细胞再分化为产生胰岛素的细胞，作为患有糖尿病的患者的治疗。

公开(公告)号：US07138486B2

公开(公告)日：2006-11-21

申请号：US10871709

申请日：2004-06-21

申请人： Joel F. Habener ,  Svetlana Mojsov

发明人： Joel F. Habener ,  Svetlana Mojsov

IPC分类号： A61K38/26 ,  A61K38/00 ,  A61K38/28 ,  A61K31/66 ,  A01N37/18 ,  A01N57/00 ,  C07K17/00 ,  C07K14/00 ,  C07K16/00 ,  C07K2/00 ,  C07K4/00 ,  C07K5/00 ,  C07K7/00

CPC分类号： A61K38/26 ,  C07K14/605

摘要： Derivatives of glucagon-like peptide I (GLP-1) and especially GLP-1 (7-37) have been found to have insulinotropic activity. The invention pertains to a composition comprising an acid addition salt of GLP-I (7-37) and to a composition comprising a carboxylate salt of GLP-I (7-37). The invention also pertains to method of treating type II diabetes mellitus by providing derivatives of GLP-I (7-37) to the patient.

摘要翻译： 已经发现胰高血糖素样肽I（GLP-1），特别是GLP-1（7-37）的衍生物具有促胰岛素活性。 本发明涉及包含GLP-1（7-37）的酸加成盐和包含GLP-1（7-37）的羧酸盐的组合物的组合物。 本发明还涉及通过向患者提供GLP-1（7-37）的衍生物来治疗II型糖尿病的方法。

公开(公告)号：US5545618A

公开(公告)日：1996-08-13

申请号：US165516

申请日：1993-12-10

申请人： Douglas I. Buckley ,  Joel F. Habener ,  Joanne B. Mallory ,  Svetlana Mojsov

发明人： Douglas I. Buckley ,  Joel F. Habener ,  Joanne B. Mallory ,  Svetlana Mojsov

IPC分类号： A61K38/00 ,  C07K14/605 ,  A61K38/26

CPC分类号： C07K14/605 ,  A61K38/00

摘要： The invention provides effective analogs of the active GLP-1 peptides, 7-34, 7-35, 7-36, and 7-37, which have improved characteristics for treatment of diabetes Type II. These analogs have amino acid substitutions at positions 7-10 and/or are truncated at the C-terminus and/or contain various other amino acid substitutions in the basic peptide. The analogs may either have an enhanced capacity to stimulate insulin production as compared to glucagon or may exhibit enhanced stability in plasma as compared to GLP-1 (7-37) or both. Either of these properties will enhance the potency of the analog as a therapeutic. Analogs having D-amino acid substitutions in the 7 and 8 positions and/or N-alkylated or N-acylated amino acids in the 7 position are particularly resistant to degradation in vivo.

摘要翻译： 本发明提供了具有改善的治疗II型糖尿病特征的活性GLP-1肽7-34,7-35,7-36和7-37的有效类似物。 这些类似物在7-10位具有氨基酸取代和/或在C-末端截短和/或在碱性肽中含有各种其它氨基酸取代。 相比于胰高血糖素，类似物可以具有增强的胰岛素产生能力，或者与GLP-1（7-37）或两者相比可能表现出增强的血浆稳定性。 这些性质之一将增强作为治疗剂的类似物的效力。 在7位和8位具有D-氨基酸取代和/或7位N-烷基化或N-酰化氨基酸的类似物特别耐体内降解。

公开(公告)号：US5831051A

公开(公告)日：1998-11-03

申请号：US538816

申请日：1995-10-03

申请人： Svetlana Mojsov ,  Yang Wei

发明人： Svetlana Mojsov ,  Yang Wei

IPC分类号： C07K14/72 ,  C07H21/02 ,  C07H21/04 ,  C12N15/00 ,  C12P21/02

CPC分类号： C07K14/72

摘要： The invention relates to an energy homeostasis peptide hormone receptor, and in particular, a second common PACAP/VIP receptor (PACAP/VIP R-2 or R-2B) cDNA expressed in human adipocytes. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) are two structurally related peptides with multiple physiological effects. The present receptor recognizes PACAP-38 and VIP with similar affinity and is coupled to the cAMP-mediated signal transduction pathway. Transcripts of the second common PACAP/VIP R-2 receptor are also found in human brain and in a number of peripheral tissues, such as pancreas, muscle, heart, lung, kidney, stomach and at low levels in the liver, while transcripts of PACAP/VIP R-2B are not found in pancreas, stomach or kidney. Comparison of the tissue distribution of PACAP/VIP R-2 to that of the other two types of PACAP receptors (PACAP-Type 1 and the other common PACAP/VIP R-1) by RNase protection shows that each of the three PACAP receptors is expressed in a unique set of human peripheral tissues. However, PACAP/VIP R-2 is receptor with broadest distribution in human tissues. Thus, some of the physiological effects of PACAP-38 and VIP in peripheral tissues, especially in pancreas and skeletal muscle, could be mediated through the energy homeostasis peptide hormone receptor, and particularly the second common PACAP/VIP receptor.

公开(公告)号：US06316596B1

公开(公告)日：2001-11-13

申请号：US09208394

申请日：1998-12-09

申请人： Svetlana Mojsov ,  Yang Wei

发明人： Svetlana Mojsov ,  Yang Wei

IPC分类号： C07K1400

CPC分类号： C07K14/72

摘要： The invention relates to an energy homeostasis peptide hormone receptor, and in particular, a second common PACAP/VIP receptor (PACAP/VIP R-2 or R-2B) cDNA expressed in human adipocytes. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) are two structurally related peptides with multiple physiological effects. The present receptor recognizes PACAP-38 and VIP with similar affinity and is coupled to the cAMP-mediated signal transduction pathway. Transcripts of the second common PACAP/VIP R-2 receptor are also found in human brain and in a number of peripheral tissues, such as pancreas, muscle, heart, lung, kidney, stomach and at low levels in the liver, while transcripts of PACAP/VIP R-2B are not found in pancreas, stomach or kidney. Comparison of the tissue distribution of PACAP/VIP R-2 to that of the other two types of PACAP receptors (PACAP-Type 1 and the other common PACAP/VIP R-1) by RNase protection shows that each of the three PACAP receptors is expressed in a unique set of human peripheral tissues. However, PACAP/VIP R-2 is receptor with broadest distribution in human tissues. Thus, some of the physiological effects of PACAP-38 and VIP in peripheral tissues, especially in pancreas and skeletal muscle, could be mediated through the energy homeostasis peptide hormone receptor, and particularly the second common PACAP/VIP receptor.

摘要翻译： 本发明涉及能量稳态肽激素受体，特别涉及在人类脂肪细胞中表达的第二种常见的PACAP / VIP受体（PACAP / VIP R-2或R-2B）cDNA。 垂体腺苷酸环化酶活化多肽（PACAP）和血管活性肠多肽（VIP）是具有多重生理作用的两种结构相关的肽。 本受体识别具有相似亲和力的PACAP-38和VIP，并与cAMP介导的信号转导途径偶联。 第二种常见的PACAP / VIP R-2受体的记录也发现在人脑和许多外周组织，如胰腺，肌肉，心脏，肺，肾，胃和肝脏中的低水平，而转录物 胰腺，胃或肾脏中未发现PACAP / VIP R-2B。 通过RNase保护比较PACAP / VIP R-2与其他两种类型的PACAP受体（PACAP-1型和其他常见PACAP / VIP R-1）的组织分布显示，三种PACAP受体中的每一种 在一组独特的人类外周组织中表达。 然而，PACAP / VIP R-2是人组织中分布最广的受体。 因此，PACAP-38和VIP在外周组织，特别是胰腺和骨骼肌中的一些生理作用可以通过能量稳态肽激素受体介导，特别是第二种常见的PACAP / VIP受体。

公开(公告)号：US5882899A

公开(公告)日：1999-03-16

申请号：US76651

申请日：1998-05-12

申请人： Svetlana Mojsov ,  Yang Wei

发明人： Svetlana Mojsov ,  Yang Wei

IPC分类号： C07K14/72 ,  G01N33/53 ,  C07K14/00 ,  C12Q1/70

CPC分类号： C07K14/72

摘要： The invention relates to an energy homeostasis peptide hormone receptor, and in particular, a second common PACAP/VIP receptor (PACAP/VIP R-2 or R-2B) cDNA expressed in human adipocytes. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) are two structurally related peptides with multiple physiological effects. The present receptor recognizes PACAP-38 and VIP with similar affinity and is coupled to the cAMP-mediated signal transduction pathway. Transcripts of the second common PACAP/VIP R-2 receptor are also found in human brain and in a number of peripheral tissues, such as pancreas, muscle, heart, lung, kidney, stomach and at low levels in the liver, while transcripts of PACAP/VIP R-2B are not found in pancreas, stomach or kidney. Comparison of the tissue distribution of PACAP/VIP R-2 to that of the other two types of PACAP receptors (PACAP-Type 1 and the other common PACAP/VIP R-1) by RNase protection shows that each of the three PACAP receptors is expressed in a unique set of human peripheral tissues. However, PACAP/VIP R-2 is receptor with broadest distribution in human tissues. Thus, some of the physiological effects of PACAP-38 and VIP in peripheral tissues, especially in pancreas and skeletal muscle, could be mediated through the energy homeostasis peptide hormone receptor, and particularly the second common PACAP/VIP receptor.

摘要翻译： 本发明涉及能量稳态肽激素受体，特别涉及在人类脂肪细胞中表达的第二种常见的PACAP / VIP受体（PACAP / VIP R-2或R-2B）cDNA。 垂体腺苷酸环化酶活化多肽（PACAP）和血管活性肠多肽（VIP）是具有多重生理作用的两种结构相关的肽。 本受体识别具有相似亲和力的PACAP-38和VIP，并与cAMP介导的信号转导途径偶联。 第二种常见的PACAP / VIP R-2受体的记录也发现在人脑和许多外周组织，如胰腺，肌肉，心脏，肺，肾，胃和肝脏中的低水平，而转录物 胰腺，胃或肾脏中未发现PACAP / VIP R-2B。 通过RNase保护比较PACAP / VIP R-2与其他两种类型的PACAP受体（PACAP-1型和其他常见PACAP / VIP R-1）的组织分布显示，三种PACAP受体中的每一种 在一组独特的人类外周组织中表达。 然而，PACAP / VIP R-2是人组织中分布最广的受体。 因此，PACAP-38和VIP在外周组织，特别是胰腺和骨骼肌中的一些生理作用可以通过能量稳态肽激素受体介导，特别是第二种常见的PACAP / VIP受体。